Archives

Liraglutide for Alzheimer’s disease . . . and other research

High dose flu vaccine and hospitalisationsWhenever flu hits the headlines, as it has this winter, attention inevitably turns to the flu vaccine. Might a higher dose be more effective in older adults? A trial set in Denmark randomised adults 65 years of age or older to receive either a high dose or standard dose quadrivalent […]

GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease

Nature Reviews Nephrology, Published online: 08 January 2026; doi:10.1038/s41581-025-01036-y Targeting incretins is emerging as an effective approach to treat cardiovascular–kidney–metabolic syndrome. Here, the authors examine the biological effects of incretins and other metabolic hormones, such as glucagon and amylin, as well as discussing current clinical data demonstrating the organ-protective effects of incretin drugs and their […]

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S (“Gubra”), a company specializing in peptide-based drug discovery and […]